Keros Therapeutics (NASDAQ:KROS – Get Free Report) and Janux Therapeutics (NASDAQ:JANX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.
Volatility & Risk
Keros Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500.
Insider and Institutional Ownership
71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and price targets for Keros Therapeutics and Janux Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Keros Therapeutics | 1 | 3 | 4 | 0 | 2.38 |
| Janux Therapeutics | 2 | 2 | 10 | 1 | 2.67 |
Keros Therapeutics presently has a consensus target price of $21.40, indicating a potential upside of 128.63%. Janux Therapeutics has a consensus target price of $36.92, indicating a potential upside of 109.43%. Given Keros Therapeutics’ higher probable upside, analysts clearly believe Keros Therapeutics is more favorable than Janux Therapeutics.
Profitability
This table compares Keros Therapeutics and Janux Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Keros Therapeutics | -256.60% | -21.76% | -19.74% |
| Janux Therapeutics | N/A | -11.71% | -10.89% |
Earnings & Valuation
This table compares Keros Therapeutics and Janux Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Keros Therapeutics | $244.06 million | 0.76 | $87.01 million | ($3.70) | -2.53 |
| Janux Therapeutics | $10.00 million | 107.79 | -$113.62 million | ($1.64) | -10.75 |
Keros Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Janux Therapeutics beats Keros Therapeutics on 10 of the 15 factors compared between the two stocks.
About Keros Therapeutics
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
About Janux Therapeutics
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
